Skip to main content

DaVita vs Tenet Healthcare: Revenue, Profit and Business Model

DaVita had $13.6B of annual revenue in FY2025 and $746.8M of net income. Tenet Healthcare had $21.3B of annual revenue in FY2025 and $2.4B of net income.

Latest financial snapshot

DaVita

Latest annual revenue
$13.6B (FY2025)
Net income
$746.8M
Net margin
5.5%
Revenue growth
+2.7% a year, FY2016–FY2025

Tenet Healthcare

Latest annual revenue
$21.3B (FY2025)
Net income
$2.4B
Net margin
11.1%
Revenue growth
+0.9% a year, FY2016–FY2025

Financial summary

DaVita

DaVita reported 2025 revenue of $13.643 billion (up 6.5% from $12.816 billion in 2024), operating income of $2.044 billion, and net income attributable to DaVita of $747 million. Adjusted diluted EPS from continuing operations was $10.78. Operating cash flow was $1.887 billion and free cash flow $1.024 billion, and the company repurchased 12.7 million shares at an average $140.09. In Q2 2026 revenue reached $3.554 billion, operating income $579 million (16.3% margin), and diluted EPS $4.02. DaVita guides to 2026 adjusted EPS of $14.10 to $15.20 and free cash flow of $1.0 to $1.25 billion. It pays no dividend and returns cash through buybacks. DaVita Inc. is a massive healthcare provider focused on kidney care, maintaining a market valuation generally over $10 billion.

Tenet Healthcare

Tenet Healthcare reported 2025 net operating revenues of $21.31 billion, up 3.1% from $20.675 billion in 2024, with consolidated adjusted EBITDA of $4.566 billion (21.4% margin). Net income available to common shareholders was $1.407 billion ($15.49 per diluted share), versus $3.2 billion in 2024, when results were inflated by gains on hospital divestitures. Momentum continued in 2026: second-quarter revenue rose 6.8% to $5.628 billion, adjusted EBITDA grew 16.3% to $1.304 billion (23.2% margin), and hospital-segment EBITDA margin improved to 18.0%. Management raised 2026 guidance to $21.9-$22.5 billion of revenue and $4.83-$5.03 billion of adjusted EBITDA, and the board added $2.0 billion to the share buyback authorization.

Revenue and profit by year

DaVita

DaVita revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$13.6B$746.8M5.5%+6.5%Source
FY2024$12.8B$936.3M7.3%+5.6%Source
FY2023$12.1B$691.5M5.7%+4.6%Source
FY2022$11.6B$560.4M4.8%-0.1%Source
FY2021$11.6B$978.5M8.4%+0.6%Source
FY2020$11.6B$773.6M6.7%+1.4%Source
FY2019$11.4B$811M7.1%-0.1%Source
FY2018$11.4B$159.4M1.4%+4.9%Source
FY2017$10.9B$663.6M6.1%+1.6%Source
FY2016$10.7B$879.9M8.2%—Source
Full DaVita financials

Tenet Healthcare

Tenet Healthcare revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$21.3B$2.4B11.1%+3.1%Source
FY2024$20.7B$4.1B19.7%+0.5%Source
FY2023$20.6B$1.3B6.4%+7.2%Source
FY2022$19.2B$1B5.2%-1.6%Source
FY2021$19.5B$1.5B7.6%+10.5%Source
FY2020$17.6B$768M4.4%-4.5%Source
FY2019$18.5B$171M0.9%+0.9%Source
FY2018$18.3B$459M2.5%-4.5%Source
FY2017$19.2B-$320M-1.7%-2.3%Source
FY2016$19.6B$176M0.9%—Source
Full Tenet Healthcare financials

Where the revenue comes from

DaVita

  • U.S. Dialysis and Related Lab Services

    About 86%

    Revenue from U.S. outpatient dialysis treatments, related laboratory services, and payer reimbursement.

  • Other Ancillary Services and Strategic InitiativesAbout 8%

    Includes integrated kidney care, value-based care arrangements, and other U.S. kidney-care initiatives.

  • International DialysisAbout 6%

    Dialysis services outside the United States across DaVita's international clinic network.

Tenet Healthcare

  • Hospital Operations (Inpatient & Outpatient Acute Care)~85%

    Revenue generated from inpatient admissions, emergency room visits, and outpatient diagnostic services across Tenet's about 50 acute care hospitals, driven by patient volume, case mix index, and negotiated commercial reimbursement rates.

  • United Surgical Partners International (USPI)~10%

    Revenue from high-margin outpatient surgical procedures performed at Tenet's more than 500 ambulatory surgery centers and 31 surgical hospitals, primarily through physician-aligned joint ventures.

  • Conifer Health Solutions~5%

    Revenue from revenue cycle management, value-based care services, and enterprise resource planning solutions provided to both Tenet's internal facilities and third-party external health systems.

Business model and strategy

DaVita

How it makes money

DaVita is paid per dialysis treatment. Most patients receive in-center hemodialysis about three times a week, while others dialyze at home with DaVita training and support. Medicare's bundled ESRD payment covers the majority of patients, but commercial insurers pay substantially more per treatment, so payer mix is the key profit driver. In Q2 2026 U.S.

Growth strategy

DaVita's strategy is to grow earnings faster than revenue. It raises revenue per treatment, controls patient care costs, and buys back shares with free cash flow. It also expands international clinics (595 centers in 14 countries by mid-2026), grows home dialysis, and scales Integrated Kidney Care risk contracts that pay for slowing disease progression and reducing hospitalizations.

Competitive advantage

DaVita's advantages are scale and operating discipline. Its dense U.S. network of 2,671 clinics, long-standing nephrologist joint ventures, purchasing scale, and experience with Medicare billing and quality programs are hard for new entrants to copy. Recurring treatment schedules create predictable demand, which supports steady free cash flow ($1.024 billion in 2025) and large share buybacks.

DaVita business model in full

Tenet Healthcare

How it makes money

Conifer's business model is scalable, relying on a combination of long-term, multi-year enterprise contracts, performance-based fee structures (where Conifer takes a percentage of the additional revenue it recovers for the client), and the licensing of its proprietary analytics and patient engagement software platforms.

Growth strategy

Tenet's strategy is to move with the shift of care from hospitals to outpatient settings. Its United Surgical Partners International (USPI) business operates more than 500 ambulatory surgery centers and 31 surgical hospitals across 29 states, mostly through joint ventures with local physicians, and it accounts for a growing share of the company's EBITDA.

Competitive advantage

Tenet's advantage is scale across about 50 acute care hospitals, 275 urgent care and occupational health centers, and more than 500 ambulatory surgery centers, which gives it weight when negotiating reimbursement with commercial insurers.

Tenet Healthcare business model in full

Questions about DaVita vs Tenet Healthcare

Which company has higher revenue — DaVita Inc. or Tenet Healthcare Corporation?

DaVita Inc. had $13.6B (FY2025), while Tenet Healthcare Corporation had $21.3B (FY2025). By latest annual revenue, Tenet Healthcare Corporation is the larger business, with DaVita Inc. showing a smaller revenue base.

What is the market cap of DaVita Inc. vs Tenet Healthcare Corporation?

DaVita Inc.'s market capitalisation stands at $12.4B, while Tenet Healthcare Corporation's is $17.2B. Tenet Healthcare Corporation carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to DaVita Inc..

How does revenue per employee compare for DaVita Inc. and Tenet Healthcare Corporation?

DaVita Inc. has $175k / employee in revenue per employee, while Tenet Healthcare Corporation has $215k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do DaVita Inc. and Tenet Healthcare Corporation make money?

DaVita Inc. and Tenet Healthcare Corporation generate revenue in fundamentally different ways. DaVita Inc.: DaVita is paid per dialysis treatment. Tenet Healthcare Corporation: Conifer's business model is scalable, relying on a combination of long-term, multi-year enterprise contracts, performance-based fee structures (where Conifer takes a percentage of the additional revenue it recovers for the client), and the licensing of its proprietary analytics and patient engagement software platforms.

Which company is valued higher relative to revenue — DaVita Inc. or Tenet Healthcare Corporation?

On a price-to-sales (P/S) basis, DaVita Inc. trades at 0.9x P/S and Tenet Healthcare Corporation at 0.8x P/S. DaVita Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Tenet Healthcare Corporation. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is DaVita Inc. bigger than Tenet Healthcare Corporation?

By last reported revenue, Tenet Healthcare Corporation ($21.3B (FY2025)) is the larger company compared to DaVita Inc. ($13.6B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the DaVita vs Tenet Healthcare overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.